Dehghanyar Pejman, Bürger Cornelia, Zeitlinger Markus, Islinger Florian, Kovar Florian, Müller Markus, Kloft Charlotte, Joukhadar Christian
Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
Antimicrob Agents Chemother. 2005 Jun;49(6):2367-71. doi: 10.1128/AAC.49.6.2367-2371.2005.
The present study tested the ability of linezolid to penetrate soft tissues in healthy volunteers. Ten healthy volunteers were subjected to linezolid drug intake at a dose of 600 mg twice a day for 3 to 5 days. The first dose was administered intravenously. All following doses were self-administered orally. The tissue penetration of linezolid was assessed by use of in vivo microdialysis. In the single-dose experiments the ratios of the area under the concentration-time curve from 0 to 8 h (AUC0-8) for tissue to the AUC0-8 for free plasma were 1.4+/-0.3 (mean+/-standard deviation) and 1.3+/-0.4 for subcutaneous adipose and muscle tissue, respectively. After multiple doses, the corresponding mean ratios were 0.9+/-0.2 and 1.0+/-0.5, respectively. The ratios of the AUC from 0 to 24 h (AUC0-24) for free linezolid in tissues to the MIC were between 50 and 100 for target pathogens with MICs between 2 and 4 mg/liter. In conclusion, the present study showed that linezolid penetrates rapidly into the interstitial space fluid of subcutaneous adipose and skeletal muscle tissues in healthy volunteers. On the basis of pharmacokinetic-pharmacodynamic calculations, we suggest that linezolid concentrations in soft tissues can be considered sufficient to inhibit the growth of many clinically relevant bacteria.
本研究测试了利奈唑胺在健康志愿者体内穿透软组织的能力。10名健康志愿者每天两次服用600毫克利奈唑胺,持续3至5天。首剂通过静脉给药。随后所有剂量均由志愿者自行口服。利奈唑胺的组织穿透情况通过体内微透析进行评估。在单剂量实验中,皮下脂肪组织和肌肉组织从0至8小时浓度-时间曲线下面积(AUC0-8)与游离血浆AUC0-8的比值分别为1.4±0.3(均值±标准差)和1.3±0.4。多次给药后,相应的平均比值分别为0.9±0.2和1.0±0.5。对于最低抑菌浓度(MIC)在2至4毫克/升之间的目标病原体,组织中游离利奈唑胺从0至24小时的AUC(AUC0-24)与MIC的比值在50至100之间。总之,本研究表明利奈唑胺可迅速穿透健康志愿者皮下脂肪和骨骼肌组织的间质液。基于药代动力学-药效学计算,我们认为软组织中的利奈唑胺浓度足以抑制许多临床相关细菌的生长。